Use of the Dose, Time, Susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning

Drug Safety

Volumn 29, Issue 7, 2006, Pages 557-566

  Callréus, Torbj̈orn ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; VASOPRESSIN ANTAGONIST; VASOPRESSIN DERIVATIVE;

ASTHMA; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; FRAGILITY FRACTURE; HEALTH CARE PLANNING; HUMAN; HYPONATREMIA; LIVER TOXICITY; NOCTURNAL ENURESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; GUIDELINES; GUIDELINES AS TOPIC; HUMANS; INTERNATIONAL COOPERATION; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 33746782066     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629070-00002     Document Type: Review

References (23)

1. International Conference on Harmonisation (ICH) E2E guideline on pharmacovigilance planning [online]. Available from URL: http://www.ich.org/ MediaServer.jser?.@_ID=1195&@_MODE=GLB [Accessed 2005 Oct 31]
2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000 Oct 7; 356 (9237): 1255-9
3. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003 Nov 22; 327 (7425): 1222-5
4. Meyboom RH, Egberts AC, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997 Jun; 16 (6): 355-65
5. Belvisi MG, Hele DJ. Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulm Pharmacol Ther 2003; 16 (6): 321-5
6. Ionescu AA, Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003 Nov; 46: 64s-75s
7. Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999 Sep; 83 (3): 153-79
8. Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol 2005 May; 59 (5): 491-4
9. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 2003 Oct; 12 (7): 551-8
10. Shapiro S. Looking to the 21st century: have we learned from our mistakes, or are we doomed to compound them? Pharmacoepidemiol Drug Saf 2004 Apr; 13 (4): 257-65
11. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005; 33 (1): 155-64
12. Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 2005 Apr; 39 (4 Suppl. 2): S83-9
13. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001 Jun; 22 (6): 298-305
14. Callreus T, Ekman E, Andersen M. Hyponatremia in elderly patients treated with desmopressin for nocturia: a review of a case series. Eur J Clin Pharmacol 2005 Jun; 61 (4): 281-4
15. Thumfart J, Roehr CC, Kapelari K, et al. Desmopressin associated symptomatic hyponatremic hypervolemia in children: are there predictive factors? J Urol 2005 Jul; 174 (1): 294-8
16. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003 Jun; 325 (6): 349-62
17. Lose G, Lalos O, Freeman RM, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003 Oct; 189 (4): 1106-13
18. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004 Sep; 172 (3): 1021-5
19. Mattiasson A, Abrams P, Van KP, et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002 Jun; 89 (9): 855-62
20. Rembratt A, Norgaard JP, Andersson KE. Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns. BJU Int 2003 May; 91 (7): 642-6
21. Boxenbaum H. Pharmacokinetics: philosophy of modeling. Drug Metab Rev 1992; 24 (1): 89-120
22. Balant LP, Gex-Fabry M. Modelling during drug development. Eur J Pharm Biopharm 2000 Jul; 50 (1): 13-26
23. Jonker DM, Visser SA, van der Graaf PH, et al. Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther 2005 Apr; 106 (1): 1-18